Corteva (NYSE:CTVA) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Corteva (NYSE:CTVA) issued its earnings results on Thursday. The company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.24 by $0.06, Zacks reports. Corteva had a return on equity of 9.95% and a net margin of 6.50%.The business had revenue of $6.38 billion for the quarter, compared to the consensus estimate of $6.60 billion. During the same period last year, the business posted $2.20 EPS. The company’s revenue was down 1.2% compared to the same quarter last year. Corteva updated its FY 2026 guidance to 3.600-3.800 EPS.

Corteva Price Performance

CTVA stock traded down $9.77 during mid-day trading on Friday, hitting $79.57. The company had a trading volume of 4,241,374 shares, compared to its average volume of 3,965,964. The company has a 50-day moving average price of $82.16 and a 200 day moving average price of $79.55. Corteva has a 12-month low of $60.53 and a 12-month high of $90.97. The company has a market capitalization of $53.22 billion, a price-to-earnings ratio of 46.93, a P/E/G ratio of 2.74 and a beta of 0.56. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07.

Corteva Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Tuesday, September 1st will be paid a $0.18 dividend. The ex-dividend date is Tuesday, September 1st. This represents a $0.72 annualized dividend and a yield of 0.9%. Corteva’s payout ratio is presently 42.35%.

Hedge Funds Weigh In On Corteva

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its position in shares of Corteva by 3.7% during the 4th quarter. State Street Corp now owns 36,570,876 shares of the company’s stock valued at $2,451,346,000 after acquiring an additional 1,290,071 shares during the last quarter. Harris Associates L P lifted its position in Corteva by 168.1% in the fourth quarter. Harris Associates L P now owns 17,026,221 shares of the company’s stock worth $1,141,268,000 after buying an additional 10,675,052 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Corteva by 5.0% during the 4th quarter. Northern Trust Corp now owns 11,731,834 shares of the company’s stock worth $786,385,000 after purchasing an additional 562,550 shares during the period. Invesco Ltd. lifted its stake in shares of Corteva by 16.7% during the 4th quarter. Invesco Ltd. now owns 11,404,960 shares of the company’s stock worth $764,474,000 after acquiring an additional 1,630,712 shares during the last quarter. Finally, Morgan Stanley boosted its stake in shares of Corteva by 1.4% during the fourth quarter. Morgan Stanley now owns 8,931,814 shares of the company’s stock valued at $598,700,000 after purchasing an additional 122,308 shares during the period. 81.54% of the stock is owned by institutional investors.

Key Headlines Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Profit beat and stronger outlook: Corteva reported second-quarter earnings of $2.30 per share, above the $2.24 consensus and up from $2.20 a year earlier. Management raised its fiscal 2026 EPS guidance to $3.60–$3.80, reflecting strong first-half performance, cost controls and growth initiatives. Corteva raises full-year profit forecast, shares fall after revenue miss
• Positive Sentiment: Operational momentum: Seed benefited from demand for newer germplasm and trait technologies, while Crop Protection saw demand for new products and licensing growth. These gains helped offset competitive pricing pressure. Corteva Delivers Strong 1H 2026, Raises FY 2026 Outlook
• Positive Sentiment: Separation remains on schedule: Corteva said it is on track for the planned October 1 spin-off of Vylor, a milestone that could provide greater strategic focus and visibility for the remaining business. Corteva Delivers Strong 1H 2026
• Neutral Sentiment: Analyst view remains constructive: Brokerages maintain a consensus “Moderate Buy” rating, while commentary highlights Corteva’s technology pipeline, pricing power and strong execution. However, some analysts see limited additional upside after the stock’s substantial outperformance. Corteva: Strong Fundamentals, Limited Upside
• Negative Sentiment: Revenue missed expectations: Second-quarter revenue was $6.38 billion versus the $6.60 billion consensus and declined 1.2% year over year. Competitive pricing dynamics and the top-line miss overshadowed the earnings and guidance improvements. Corteva quarterly earnings report
• Negative Sentiment: Valuation and execution concerns: With shares trading at a premium valuation, investors may demand continued earnings growth. The upcoming separation also introduces transaction and execution risks, limiting the market’s reaction to the improved forecast.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Morgan Stanley raised their target price on shares of Corteva from $84.00 to $95.00 and gave the stock an “overweight” rating in a report on Thursday, May 28th. BNP Paribas Exane upped their price target on Corteva from $74.00 to $77.00 in a research report on Wednesday, May 6th. Rothschild & Co Redburn raised their price objective on Corteva from $80.00 to $90.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Wells Fargo & Company lifted their price target on shares of Corteva from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Tuesday, April 21st. Finally, The Goldman Sachs Group raised their price objective on shares of Corteva from $88.00 to $96.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Corteva currently has a consensus rating of “Moderate Buy” and an average target price of $90.19.

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.